Phase 4 Heart Disease Trial, Recruiting NCT04728516 Sponsor: Qilu Hospital of Shandong University Condition: Heart Disease
Back to Heart Disease

Phase 4 Heart Disease Trial, Recruiting

NCT04728516
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with a type of heart attack (called ACS) and had a procedure to open blocked arteries (called PCI/stenting), and have been taking two blood-thinning medications together for at least 6 months afterward
  • You have tested positive for a stomach bacteria called Helicobacter pylori (H. pylori)
  • You are 18 years old or older
  • You (or your authorized representative) are willing and able to sign a consent form to participate

Who may not be able to join:

  • You have a past history of bleeding from a stomach or intestinal ulcer
  • You have been regularly taking stomach acid-reducing medications (such as PPIs or H2 blockers) for a long time
  • You have enlarged veins in your food pipe or stomach, or have had part of your stomach surgically removed
  • You are currently taking blood-thinning medications such as warfarin or similar drugs (factor X or factor II inhibitors)
  • You recently received clot-dissolving (fibrinolytic) therapy within the past 24–48 hours before joining
  • You had heart bypass surgery (CABG) within the last 30 days, or have one planned
  • You currently have active bleeding or a condition that affects your blood's ability to clot (confirm with trial site)
  • You have liver or kidney disease with certain abnormal test results, including elevated kidney or liver markers above specific levels (confirm with trial site for exact values)
  • You have had a bleeding stroke, or have a brain tumor, abnormal blood vessels in the brain, or a brain aneurysm
  • You have anemia, meaning your blood count is below a certain level for your sex (confirm with trial site for exact values)
  • You are currently taking steroid medications (such as corticosteroids)
  • You have taken antibiotics or other medications that affect stomach bacteria within the past month
  • You have a known allergy to aspirin, clopidogrel, ticagrelor, pantoprazole, penicillin, or other medications used in this trial
  • You are pregnant, breastfeeding, or of childbearing age and unwilling to use contraception during the trial
  • You have a serious illness such as cancer where life expectancy is estimated to be less than 1 year
  • You have taken part in another drug clinical trial within the past 30 days, or are currently in one
  • You have a diagnosed mental illness or severe psychological condition
  • You are unable to communicate or describe your own symptoms
  • The trial doctor decides for any other reason that participation is not appropriate for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Yu-guo Chen, MD, PhD, Qilu Hospital of Shandong University

Phone: +8618560083065

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Qilu Hospital of Shandong University
Registry
ClinicalTrials.gov
Start date
12 April 2023
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Gastrointestinal bleeding of 6 months in patients with ACS after PCI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov